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SELECTION OF THE MONTH 
Big title: Implementation of four simple interventions can reduce premature 
alcohol related deaths 
Data from many, many sources have confirmed that there is a direct relationship 
between the amount of alcohol consumed and the risk of death at the individual and at 
a national level. The article by Sheron, provides an excellent evidence-based 
insight into the existing data and proposes 4 relatively simple solutions to tackle 
the problem. 
 Regular incremental above inflation tax increases 
 Minimum price for alcohol,  
 Effective protection of children from alcohol marketing and  
 Low-level interventions from clinicians. 
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Implementation of these proposed solutions require concerted action from all involved. 
 
Small Title: Cirrhosis: New therapeutic strategies for Portal Hypertension 
Predicting the long-term HCC risk under anti-viral HBV treatment 
 
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Kupffer cells, uric acid and glucagon-like peptide-1 (GLP-1) in NAFLD 
Kupffer cells promote liver inflammation in patients with NASH, yet the molecular 
mechanisms are largely unknown. In this issue Robert et al. demonstrated a role of the 
glucocorticoid receptor-induced leucine zipper (GR-GILZ) axis in obesity-induced 
liver inflammation. By using a combination of primary cell culture, and pharmacological 
and genetic experiments in mice, the authors provide evidence that obesity is 
associated with a downregulation of the GR-GILZ axis in Kupffer cells, which promotes 
liver inflammation. This molecular pathway represents a potential novel target for 
therapy in patients with metabolic syndrome and NASH. In another study, Wan et al. 
studied the mechanisms liking hyperuricemia, NAFLD and insulin resistance. The 
authors demonstrate that uric acid directly induces hepatocyte fat accumulation, insulin 
resistance, and insulin signaling impairment both in vivo and in vitro. Interestingly, this 
elegant study provides evidence that the activation of the inflammasome NLRP3 (for 
nucleotide-binding oligomerization domain [NOD]-like receptor [NLR] family, 
pyrin domain containing 3) is a major mechanism mediating the deleterious effects 
of uric acid in NAFLD. In a third NAFLD study publish in this issue, Junker et al. studied 
the effects of GLP-1 on glucagon secretion in patients with NAFLD and matched 
controls. Patients with NAFLD exhibited fasting hyperglucagonaemia, but intact GLP-
1-mediated glucagon suppression independently of plasma glucose concentrations. 
These results suggest that preserved glucagonostatic effect and increased 
insulinotropic effects of GLP-1 in patients with NAFLD may be important to maintain 
normoglycaemia. These three studies on NAFLD revealed potential targets for therapy 
and also uncovered key metabolic effects of GLP-1 in patients with fatty liver disease. 
 
HEPATITIS C 
Is there a risk of lactic acidosis when treating decompensated HCV disease with 
nucleosidic polymerase inhibitors? Treatment of acute HCV infection in HIV 
coinfected patients 
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The safety profile of the currently licensed interferon-free direct acting antiviral 
regimens is remarkably high when studied in patients with HCV-induced compensated 
chronic liver disease. The study by Welker et al., however, raises concerns regarding 
the safety of nucleosidic HCV NS5B HCV polymerase inhibitor-based regimens when 
given in patients with decompensated disease. They described a high number of 
severe adverse events including seven episodes of lactic acidosis in 35 patients 
with decompensated cirrhosis who have been treated with sofosbuvir plus 
ribavirin combination. Although causality of the findings might be questioned to some 
extend and further evaluations are needed - as also highlighted in the Editorial by Jay 
Hoofnagle in this issue – the current study should remind us that the safety profile of 
nucleosidic HCV polymerase inhibitors had not been fully determined within the pivotal 
trials and rare adverse events may occur in special patient populations. 
The optimal treatment approach for acute HCV infection in HIV positive men having 
sex with men (MSM) is still debated. So far the combination of peg-interferon alfa plus 
ribavirin applied for 24 weeks is recommended. Whether the addition of the first 
generation protease inhibitor boceprevir may allow for shortening treatment durations 
to 12 weeks in rapid week 4 responders was evaluated in a large number of coinfected 
patients in a prospective Dutch multicentre study by Hullegie et al. A 12 week triple 
regimen consisting of peg-interferon alfa plus weight-based ribavirin and 
boceprevir resulted in a 100% cure rate in rapid responders. As direct acting 
antivirals are not approved for acute HCV infection and their use is also limited by high 
costs, the short-term first generation triple regimen can be considered a valid treatment 
option in this setting. 
 
HEPATITIS B 
Non-invasive fibrosis assessment in chronic HBV infection, the long-term risk of 
hepatocellular carcinoma (HCC) under anti-viral treatment, antisense approach 
to treat HBV infection 
Tests for non-invasive fibrosis assessment have increasingly replaced liver biopsy as 
a tool to stage patients with chronic HCV infection. However, their role and accuracy 
in chronic HBV infection have been less well explored. Kim et al. evaluated the 
performance of two commonly used scoring systems for chronic hepatitis C, the 
‘aspartate aminotransferase (AST)-to-platelet ratio index’ (APRI) and the ‘fibrosis index 
based on four factors’ (FIB-4), taking account of AST, ALT, platelet count and patient 
4 
 
age, in a large cohort of 575 patients with chronic hepatitis B. The study results 
demonstrate the inability of both the APRI and FIB-4 to classify stage of fibrosis 
correctly as well as to follow liver fibrosis evolution in patients under antiviral 
therapy. One should be aware of the limitations when using approaches to assess 
fibrosis non-invasively with proven accuracy in HCV infection in other chronic liver 
diseases and disease specific characteristics have to be taken into account when trying 
to assess the dynamic of fibrosis progression in chronic HBV infection.  
Despite effective control of HBV replication under treatment with highly effective oral 
antivirals, HCC may still occur with an annual rate ranging from approximately 0.01 to 
5%. Identifying the patients at risk is important for optimizing long-term surveillance 
strategies, and several HCC risk scores have been established in Asian populations 
which, however, offer poor to moderate predictability in Caucasian patients. In order to 
develop an accurate HCC risk score in Caucasian patients, Papatheodoris et al. 
performed a large multicentre study including 1,815 patients who received either 
entecavir or tenofovir for ≥12 months. The authors show that a score based on 
baseline age, gender and platelets, called the PAGE-B score, represents a simple 
and reliable approach for predicting the 5-year HCC risk in Caucasians. If 
validated by others, the PAGE-B score, may offer a way for new surveillance strategies 
in patients under long-term antiviral therapy.   
The HBV genome in form of the covalently closed circular DNA molecule (cccDNA) 
serves amongst others for the production of several viral transcripts used for the 
production of subviral particles composed of viral envelope proteins (HBsAg particles) 
or HBeAg. These proteins are secreted from infected cells and have been implicated 
to play an important role in HBV persistence by mediating HBV-specific T cell anergy 
as well as evasion of HBV to the immune system. The potential of antisense 
oligonucleotide-mediated antiviral therapy to specifically reduce HBV antigenemia was 
elegantly evaluated in vitro and in vivo by Billioud et al. in HBV transgenic mouse and 
cell culture models. The antisense approach showed pan-genotypic antiviral 
activity herby significantly reducing HBsAg levels and cccDNA-driven HBV gene 
expression. The here for the first time described antisense strategy represents a 
promising novel therapeutic modality for treating chronic HBV infection. 
 
CIRRHOSIS 
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New approaches for treatment of portal hypertension by targeting coagulation 
and ammonia, biomarkers for ASH and ACLF 
Pharmacological strategies for the treatment of portal hypertension are limited to non-
selective beta-blockers. Two excellent papers in the current issue describe two novel 
strategies that can be potentially translated clinically to provide patient benefit. The 
first, is the demonstration by Garcia-Pagan et al. that enoxaparin, an anticoagulant 
reduced the severity of portal hypertension when administered chronically to 
animal models. They mechanisms through which this is achieved are through 
reduction in the activation status of stellate cells and by effects on reducing hepatic 
microthrombi. The second is a study by Rombouts et al. who show for the first time 
that ammonia, a metabolite that accumulates in liver failure and commonly associated 
with hepatic encephalopathy can produce dysfunction of the hepatic stellate cells. 
Reduction in the concentration of ammonia using a drug in development, OCR-
002, reduced the severity of portal hypertension. 
Alcoholic hepatitis is characterized by hepatic neutrophil infiltration but the 
mechanisms are unclear.  In a very important and novel study, Tilg et al. studied the 
role of neutrophil gelatinase-associated lipocalin (NGAL, encoded by lipocalin 2), a 
positive acute-phase protein, which can recruit immune cells, in the pathogenesis of 
ASH. They showed that the concentration of NGAL is increased in the liver 
infiltrating neutrophils in ASH and NGAL is a possible target of therapy.  
ACLF is a recently defined entity. Gronbaek et al. used samples acquired from the 
CANONIC study to explore whether the current clinical prognostic scores could be 
improved by measuring the concentration of the scavenger receptor that is usually 
expressed on macrophages. They convincingly show the prognosis of patients 
can be predicted significantly better if soluble CD163 is added to the CLIF-ACLF 
score reaching a concordance index of 0.80. Their data provide a novel biomarker 
for ACLF patients. 
 
LIVER TRANSPLANTATION 
Huge variability in acceptance rates of organs for sick patients across the US. 
Improvement in selection criteria for transplantation for hepatocellular 
carcinoma (HCC) 
Due to donor shortages, many patients die on the waiting list despite the existence of 
a policy whereby organs at prioritized to the sickest patients. Goldberg et al. provide 
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some startling observation form studies of the Organ Procurement and Transplantation 
Network that aimed to determine whether there was a difference in the acceptance 
rate for these organs by different transplant centers and the effect of turning down the 
organs for the sickest patients on outcomes. The results show that there was a huge 
variability in the acceptance rates of organs offered for the sickest patients and 
this resulted in significantly higher death rates. 
The Milan criteria are the current gold standard for the selection of patients with HCC 
for liver transplantation but with improvement in imaging techniques there is an 
opportunity for better selection. Hong et al. studied HCC patients undergoing live 
donor liver transplantation and found that the risk of recurrence was best 
predicted using PET scanning using FDG and alpha-fetoprotein levels, which 
was significantly better than the Milan criteria. These exciting new data will need 
to be further validated. 
 
SYSTEM BIOLOGY 
Modeling identifies novel therapeutic target for reducing ammonia 
Understanding relationships in complex systems where multiple variables are involved 
is difficult using experimental techniques alone. Systems biology tools, which involve 
modeling, are likely to be useful in this situation. Ghallab et al. provide intriguing data 
from studies of ammonia metabolism. They built an integrated model of ammonia 
metabolism and found that the model underestimated ammonia consumption 
after liver injury when working with known pathways. Further interrogation of 
the system revealed that an enzyme involved in intermediary metabolism, 
glutamate dehydrogenase (GDH) was likely to be involved. If these data can be 
successfully translated into humans, a novel therapeutic strategy can be the result. 
 
